The NICE boss has called for “more data transparency” from pharma in a bid to improve the relationship between the pharma and healthcare industries.
Speaking at a summit held recently in London, the chief executive of the National Institute for Health and Care Excellence (NICE), Sir Andrew Dillon, called for “more data transparency” from the pharma industry to improve its relationship with the healthcare industry.
Sir Andrew, who was speaking at the Economist Pharma Summit, said it would “great” if pharma companies could make evaluation information available before a drug was released on the market to ensure the drugs’ effects were more widely understood.
The NICE boss said the increase in data transparency would “improve our relationship with the industry” and suggested that the health industry also had a role to play in boosting access to drug information.
He called for “a joint effort to make it possible for us to understand what is happening to drugs inside the system once the products are in routine use”.
“Our systems have to want to put the effort into collecting clinical data as much as they put the effort into collecting billions of data items on the financing of the system, which we do rather well,” he said.
Sir Andrew’s comments add to widespread calls from campaigners and patient groups in recent months for clinical data to be more accessible, while there have been gradual changes within the pharma industry to make the drug’s market more transparent and improve their reputation.
http://www.pharmafield.co.uk/Pf-Fox-News/General/2014/03/e28098More-transparencye28099-from-pharma-says-NICE?
Speaking at a summit held recently in London, the chief executive of the National Institute for Health and Care Excellence (NICE), Sir Andrew Dillon, called for “more data transparency” from the pharma industry to improve its relationship with the healthcare industry.
Sir Andrew, who was speaking at the Economist Pharma Summit, said it would “great” if pharma companies could make evaluation information available before a drug was released on the market to ensure the drugs’ effects were more widely understood.
The NICE boss said the increase in data transparency would “improve our relationship with the industry” and suggested that the health industry also had a role to play in boosting access to drug information.
He called for “a joint effort to make it possible for us to understand what is happening to drugs inside the system once the products are in routine use”.
“Our systems have to want to put the effort into collecting clinical data as much as they put the effort into collecting billions of data items on the financing of the system, which we do rather well,” he said.
Sir Andrew’s comments add to widespread calls from campaigners and patient groups in recent months for clinical data to be more accessible, while there have been gradual changes within the pharma industry to make the drug’s market more transparent and improve their reputation.
http://www.pharmafield.co.uk/Pf-Fox-News/General/2014/03/e28098More-transparencye28099-from-pharma-says-NICE?
No comments:
Post a Comment